Graft failure (GF) remains an obstacle to survival after allogeneic hematopoietic stem cell transplantation. However, differentiating GF from delayed engraftment (DE) can be difficult. Host CD8 + lymphocytes have been reported to mediate graft rejection, but the impact of macrophages on DE or GF is yet to be clarified. Peri-engraftment bone marrow (BM) specimens of 32 adult patients with normal engraftment, DE or GF were retrospectively evaluated to identify the potential associations of CD163 + macrophage and CD8 + lymphocyte infiltration into BM. The macrophage or CD8 + lymphocyte number/total nucleated cell number was defined as the Mac ratio and CD8 ratio, respectively. Both DE and GF groups had significantly higher Mac ratios at day 14 than the normal group (P o0.0001), but no significant difference was observed between the DE and GF groups (P = 1.000). The CD8 ratio at day 14 was significantly higher in the GF than in the normal group (P = 0.005), whereas the CD8 ratios of the DE and normal groups were similar (P = 0.07). A high Mac ratio at day 14 was associated with a risk of DE or subsequent GF. Patients with increased CD8 ratio at day 14 had a further risk of GF. The Mac ratio and the CD8 ratio appear to be well suited for predicting engraftment status.
INTRODUCTION
Delayed engraftment (DE) and subsequent graft failure (GF) are critical complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) that often lead to severe infection. 1, 2 Longer time to engraftment was reported to be associated with increased transplant-related mortality and worse overall survival (OS). 3 Risk factors for GF have been investigated in previous studies. Primary disease not in remission, 4 HLA-mismatched transplantation, 5, 6 donor-specific HLA Abs, [7] [8] [9] [10] T-cell depletion, 11 reduced-intensity conditioning, 12, 13 and limited dosage of total nucleated or CD34 + cell counts and colony-forming units in cord blood transplantation (CBT) were described as adverse factors associated with engraftment. [14] [15] [16] [17] [18] [19] However, it is not yet possible to precisely differentiate GF from DE or normal engraftment prospectively.
GF is initiated by host precursor CD8 + cytotoxic T-cells that survive the transplant preparative conditioning regimen. Such precursor cytotoxic T-cells generate a host-versus-graft rejection response as they clonally expand in response to allo-Ags present on the donor stem cell population. 20 On the other hand, it is well known that HSCT from a T cell-depleted graft has a higher probability of rejection. [21] [22] [23] [24] [25] [26] Therefore, donor-derived CD8 + lymphocytes contribute to engraftment, but host CD8 + lymphocytes mediate GF. In addition, we previously reported that increased numbers of hemophagocytic macrophages were associated with higher incidences of death due to GF and other transplant-related mortality. 27 Hemophagocytic syndrome (HPS) is a syndrome caused by activated macrophages and often diagnosed by the recipient bone marrow (BM) specimen, which is observed more frequently in CBT than in other graft sources. 28 However, it has been reported that hemophagocytosis in BM is not always visible in the initial stage of macrophage activation syndrome. 29 Furthermore, though HPS is clinically diagnosed by the manifestations of fever, pancytopenia and hyperferritinemia, these features are not specific to patients with HPS in the setting of post-allo-HSCT, and neither the diagnosis of HPS nor an increase of macrophages in the BM is sufficient for the prediction of GF. [30] [31] [32] Thus, it is desirable to establish a better predictive marker system for GF throughout the peri-engraftment period.
Therefore, we hypothesized that enumeration of CD8 + T lymphocytes and macrophages in BM would make it possible to describe the variety of engraftment kinetics resulting in different clinical outcomes. In the present study, the impacts of activated CD8 + T lymphocytes and macrophages in recipient BM on engraftment were evaluated retrospectively. Furthermore, a system for predicting GF by combining quantitative determinations of CD8 + T lymphocytes and CD163 + macrophages in recipient BM is proposed. from this study because no patient with DE or GF was observed after PBSC transplantation.
HLA typing of recipients and donors was performed in A, B, C and DRB1 loci at high resolution. Both serological and allele HLA matching was determined in the 8 loci. Conditioning regimens included both conventional myeloablative conditioning and reduced-intensity conditioning. Myeloablative conditioning consisted of cyclophosphamide and TBI-based regimens, whereas reduced-intensity conditioning consisted mainly of fludarabine 125 mg/m 2 and melphalan 140-180 mg/m 2 . GvHD prophylaxis was either cyclosporine A or tacrolimus combined with short-term methotrexate. G-CSF was administered after transplantation in all patients until neutrophil engraftment was achieved. Serial samples of peripheral blood mononuclear cells after HSCT were analyzed for chimerism using a PCR of informative microsatellite regions after transplantation, as described previously. 33 This study was approved by the institutional review board of Japanese Red Cross Nagoya First Hospital, and all patients provided informed consent in accordance with the Declaration of Helsinki.
Definitions
Neutrophil engraftment was defined as achievement of an ANC ⩾ 500/mm 3 for 3 consecutive days. Platelet engraftment was defined as achievement of platelet count ⩾ 20 000/μL without transfusion support for 7 consecutive days. DE was defined as neutrophil engraftment that was observed later than day 20 and day 27 post BMT and CBT, respectively. GF was defined as the absence of absolute neutrophil recovery after day 20 post BMT or day 27 post CBT, including those who underwent second salvage transplantation.
HPS post allo-HSCT was diagnosed using the previously reported criteria as described in Supplementary Method. 34 BM examination BM aspiration was routinely performed on day 14 ± 7 and day 28 ± 7 after HSCT. All specimens were fixed in 10% formalin solution, embedded in paraffin, and stained with hematoxylin and eosin. Immunohistochemical analysis of BM clots was also performed by staining T lymphocytes with anti-CD8 monoclonal Ab (Novocastra, Newcastle, UK) and macrophages with anti-CD163 monoclonal Ab (Novocastra), as previously described.
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CD163 is a member of the scavenger receptor cysteine-rich superfamily and has been recognized as a nonclassical activation marker for macrophages, playing a major role in the scavenging components of damaged cells. Furthermore, macrophages with an unrestrained proinflammatory activation status were recently demonstrated to be CD163 + along with other classical M1 marker. 36 Thus, we used staining with CD163 as an activation marker.
BM clot sections were retrospectively reviewed, and the total number of CD163 + macrophages was counted in three fields per sample under 200-fold magnification. The ratio of macrophages (Mac ratio) was calculated by dividing the number of macrophages by the total nucleated cell counts per field. The ratio of CD8 + lymphocytes (CD8 ratio) was obtained by dividing the number of the CD8 + cell count by the total nucleated cell counts per field. In addition, the total area of CD163 + macrophages was measured with a digital microscope (BZ-9000, Keyence, Japan). To evaluate its activation, the size of a macrophage (Mac area) was also estimated by dividing the total CD163 + area by the number of CD163 + macrophages per field.
As control samples, 9 and 12 BM specimens of day 14 and day 28 post transplantation in a total of 13 patients who achieved normal engraftment, 11 of which were post BMT and 2 were post CBT, were selected by matching the patient age, disease risk, graft source, conditioning regimens, HLA disparity and infused stem cell number. Among the 12 patients with DE, 11 BM samples at day 14 and 10 samples at day 28 were available, whereas a total of 6 BM samples at day 14 and 7 samples at day 28 were available in 7 patients with GF.
Statistical analysis
Demographic factors and disease characteristics were compared using the standard χ 2 -test or Fisher's exact test for categorical data, and the Mann-Whitney U-test for continuous variables. The Mac ratio, CD8 ratio and Mac area were analyzed by one-way analysis of variance. The probabilities of OS were estimated using the Kaplan-Meier method, and the log-rank test was used for univariate comparisons. Survival time was calculated from the date of HSCT to the date of death or last contact. A significance level of Po0.05 was considered significant for all analyses. All statistical analyses were performed by Stata version 12 (Stata Corp., College Station, TX, USA). Mac ratio and CD8 ratio predict graft failure N Kawashima et al
RESULTS

Patient characteristics
A total of 150 patients with normal engraftment and 19 (11.2%) patients with DE or GF were included in the present study (Table 1) . Compared with the normal group, HSCT from HLA-mismatched or unrelated donors was more prevalent in the DE or GF group. Total nucleated cells and CD34 + cell numbers were significantly lower in patients with DE or GF after BMT. Neutrophil and platelet engraftments were observed at a median of 22.5 and 41.5 days, respectively, post BMT in patients with DE, significantly later than at 16 and 26 days post BMT in patients with normal engraftment.
The characteristics of the 19 patients with DE (n = 12, 63.2%) or GF (n = 7, 36.8%) are shown in Supplementary Table S1 . There was no significant difference in patients' age, sex, primary disease risk, HLA disparity, GvHD prophylaxis or infused cell counts. Significantly more CB recipients (n = 4, 40%) than BM recipients (n = 3, 20%) were observed to have GF (P = 0.009). All patients with GF received myeloablative conditioning prior to HSCT. HLA Abs were screened in 8 of 10 patients with DE or GF receiving HLA-mismatched graft sources, and were detected in two DE patients, one of which was specific to donor HLA.
T-cell chimerism of seven patients with GF revealed ⩾ 95% recipient-derived T-cells in the peripheral blood of 5 patients (71.4%) at a median of day 26 post HSCT (range, days . Among 12 patients with DE, T-cell chimerism in the peripheral blood of five patients was evaluated. Recipient-derived T-cells were detected at a median of 9.0% (range, 2.4-13.7) on day 14 and ⩾ 95% donor-derived T-cells were observed in every patient at a median of day 28 post HSCT (range, days 24-41).
Macrophage activation in BM BM clot sections stained with hematoxylin and eosin or anti-CD163 monoclonal Ab are shown in Figure 1 . Increased numbers and enlargement of CD163 + macrophages indicating their activation were observed in the BM specimens of DE and GF (Figures 1e and f) . From a clinical viewpoint, whereas 43% mature macrophages were present in the BM of all patients, only 6 (50%) patients in the DE group and 1 (14.3%) patient in the GF group fulfilled the diagnostic criteria of HPS. ), whereas there was no significant difference between DE and GF (Figure 2b , P = 1.00). (Figure 3d ) in the normal engraftment, DE and GF groups, respectively. The CD8 ratio on day 14 was significantly higher in the GF group than in the normal group (P = 0.005), whereas no significant difference was observed between the normal and DE groups and between the DE and GF groups (P = 0.07 and 0.42, respectively) ( Figure 3c ). The CD8 ratio was significantly higher in the DE (P = 0.03) and GF (P o 0.0001) groups compared with the normal engraftment group on day 28 ( Figure 3d ). The CD8 ratio was significantly higher in GF than in DE (P o0.0001) as well at day 28. To clarify whether a combination of the Mac ratio and the CD8 ratio can predict the incidence of GF, scatter diagrams by the Mac ratio and the CD8 ratio were generated ( Figure 4 ). On day 14, all GF cases were plotted in the area of Mac ratio 40.4 and CD8 ratio 40.1, although the difference between DE and GF was not clear (Figure 4a ). On day 28, most cases of GF were plotted within the area of Mac ratio 40.4 and CD8 ratio 40.5, and the difference between DE and GF was clear (Figure 4b ). Patients were stratified to each engraftment status using the Mac ratio and the CD8 ratio on both day 14 (P o 0.0001) and day 28 (P o 0.0001) with a threshold of 0.4 for the Mac ratio, 0.1 for the day 14 CD8 ratio and 0.5 for the day 28 CD8 ratio, as demonstrated in Table 2 . A total of 5 of 7 patients (71.4%) with GF received second salvage CBT. As a treatment for DE, dexamethasone palmitate, liposome-incorporated dexamethasone, was administered to 2 of 17 patients (11.8%) as macrophage-targeted therapy, 30 resulting in successful engraftment.
DISCUSSION
GF is a life-threatening complication that increases morbidity and mortality after allo-HSCT and requires immediate treatment. Host T-cells are commonly regarded as the main contributors to immunological rejection after allo-HSCT. [37] [38] [39] [40] The role of macrophages during the peri-engraftment period has not been clarified, except for the possible association with hemophagocytosis. 41, 42 We and others previously reported that activation of macrophages in BM early in the post-transplant period was associated with impaired hematopoietic recovery, higher transplant-related mortality rates and lower OS rates, suggesting that early macrophage activation has a significant impact on outcomes of allo-HSCT. 27, 28, 43 However, as shown in this study, the diagnostic criteria for HPS are not adequate for predicting DE or GF in the setting of allo-HSCT. 34 In the current study, the impacts of activated macrophages and CD8 + T lymphocytes on engraftment status were histopathologically evaluated by monitoring their ratios in BM, and they were defined as the Mac ratio and the CD8 ratio. Since the Mac ratio and the CD8 ratio are calculated by the number of macrophages and total nucleated cells, it also demonstrates delay in the recovery of total nucleated cells. This study showed that the Mac ratio in day 14 BM could be a new index predicting DE and that a high CD8 ratio increases the probability of GF. In the present study, not only the ratio, but also the area of macrophages was significantly enlarged in patients with DE and GF on day 28, indicating their activation in BM. Although the Mac ratio of patients with GF was significantly higher than of those with DE on day 28, it was not possible to predict GF in advance using only the Mac ratio on day 14. On the other hand, an increased CD8 ratio indicating the expansion of recipient T-cells had been already observed on day 14 in patients with GF, which was distinct from the normal engraftment group (P = 0.005) and similar to that of the DE group (P = 0.07); this could be a predictive marker of GF. Considering these results, we assume that both activated macrophages and CD8 + T-cells could mediate DE or GF, and that those with elevated Mac ratios on day 14 have the possibility of DE, whereas those with increases of both CD8 + lymphocytes and macrophages on day 14 are at high risk of GF. The combination of the Mac ratio and the CD8 ratio may be able to serve as an accurate index for predicting engraftment status.
However, to understand the trigger of their activation, further investigation is required. In previous studies, natural killer cells have been also described to mediate acute BM rejection. 37 Even in SCID with severe T-cell lymphocytopenia and a lack of Ag-specific T-cell immune responses, rejection without preconditioning was reported. 44 In SCID patients, higher numbers of natural killer cells showed poorer recovery of T-cell populations after HSCT, compared with lower numbers or without natural killer cells. 45 Thus, there remains a possibility that rejection reaction is initiated by natural killer cells, and then handed on to CD8 + T lymphocytes and macrophages.
The origins of activated T lymphocytes and macrophages are still under debate. It can be considered that increased CD8 + T-cells in BM are recipient-derived, because we confirmed that 495% of peripheral T-cells were recipient origin, which is consistent with previous studies. 23, 25, 46 Donor-derived CD8 + T-cells are commonly considered to contribute to engraftment, because several lines of clinical and experimental observations have demonstrated that an increased incidence of GF was observed after the depletion of donor T-cells from allo-HSCT grafts. 21, 26, 47, 48 Thus, we believe the CD8 + T lymphocytes in the BM were of recipient origin. Conversely, the origin of activated macrophages is not fully elucidated. In a previous study, the combination of immunostaining with anti-CD163 monoclonal Ab to detect macrophages and genotyping by FISH using X-or Y-chromosome-specific probes demonstrated that 80% of the macrophages in the BM were of recipient origin at the onset of HPS post allo-HSCT. 49 In another study, macrophages of HPS after HSCT were found to be donor-derived by PCR-based assays with microsatellite polymorphisms. 50 Further investigations to explain the clear dissociation of the above results are needed. The origin of macrophages may depend on the situation, and GvHD prophylaxis or other transplant-associated factors.
In the present study, an increased Mac ratio was associated with lower OS, which was consistent with our previous report evaluating hemophagocytic macrophages in BM. 27 Early prediction of DE using the Mac ratio opens the possibility of treatment targeting activated macrophages. However, the optimal timing and appropriate medication have not yet been determined. Careful consideration is also required on macrophage-targeted treatment because another possibility is that the activation of macrophages in BM is not causative but the result of ongoing GF. Since the current study was a retrospective analysis including a limited number of patients at a single institution, a further study with an increased number of patients is warranted to confirm these results. Mac ratio and CD8 ratio predict graft failure N Kawashima et al
